n(g),n(g')-dimethyl-l-arginine has been researched along with Coronary Artery Disease in 76 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We sought to investigate whether ranolazine, a novel antianginal medication with no effect on heart rate or blood pressure, improves endothelial function in patients with stable coronary artery disease (CAD)." | 9.14 | Ranolazine improves endothelial function in patients with stable coronary artery disease. ( Coppola, JT; Deshmukh, SH; Hermance, EV; Infantino, MN; Mindrescu, C; Patel, SR; Pinassi, E; Staniloae, CS, 2009) |
| "Studies regarding the predictive utility of the blood level of asymmetric dimethylarginine (ADMA) in patients with coronary artery disease (CAD) have yielded the conflicting findings." | 9.12 | Prognostic value of asymmetric dimethylarginine in patients with coronary artery disease: A meta-analysis. ( Dai, Y; Mao, H; Ye, J; Zhang, J; Zheng, W, 2021) |
| "Pioglitazone rapidly improves endothelial function in non-diabetic patients with coronary artery disease." | 9.12 | Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. ( Ambrose, J; Bernaski, E; Coppola, J; El-Khally, Z; Kurian, D; Mandadi, V; Morlote, M; Pinassi, E; Staniloae, C, 2007) |
| "Previous studies have shown that Asymmetric Dimethyl Arginine (ADMA) is increased significantly during coronary artery diseases (CAD)." | 7.88 | Evaluation of serum Asymmetric Dimethyl Arginine concentrations in coronary artery disease patients without traditional cardiovascular risk factors. ( Ayati, N; Elyasi, S; Ghayour-Mobarhan, M; Mohammadpour, AH; Moohebati, M; Sahebkar, A, 2018) |
| " The aim of our study was to determine the predictive value of plasma asymmetric dimethylarginine (ADMA), homocysteine, and high-sensitivity C-reactive protein (hsCRP) levels for occult coronary artery disease (CAD)." | 7.81 | Predictive value of plasma asymmetric dimethylarginine, homocysteine, and high-sensitive CRP levels in occult coronary artery disease: A multidetector-row computed tomography study. ( Başaran, Y; Geçmen, Ç; Gürel, E; Karaahmet, T; Mutlu, B; Tigen, K, 2015) |
| "Asymmetric dimethylarginine (ADMA) plays role in the pathogenesis of coronary artery disease and related mortality and morbidity through a number of mechanisms." | 7.81 | Asymmetric dimethylarginine is not a good predictor of ischemia using myocardial perfusion scintigraphy. ( Aşik, M; Aslantaş, Y; Bulur, S; Doğan, AS; Erkan, ME; Ilçe, HT; Memişoğullari, R; Uçgun, T; Yildirim, M; Yildiz, N; Yilmaz, A, 2015) |
| "To determine whether 3 biomarkers, L-arginine, asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA), can predict outcomes in patients with Kawasaki disease (KD)." | 7.80 | Asymmetric and symmetric dimethylarginine are associated with coronary artery lesions in Kawasaki disease. ( Huang, YH; Kuo, HC; Lee, CP; Tain, YL, 2014) |
| "Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthesis inhibitor, and insulin resistance (IR) have been implicated in atherogenesis." | 7.79 | Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: a cross-sectional study. ( Golay, A; Kruszelnicka, O; Surdacki, A, 2013) |
| "The endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) is increased in patients with coronary artery disease and may regulate function of circulating angiogenic progenitor cells (APCs) by small regulatory RNAs." | 7.76 | Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. ( Bauersachs, J; Ertl, G; Fiedler, J; Fleissner, F; Galuppo, P; Gupta, SK; Jazbutyte, V; Kneitz, S; Mayr, M; Thum, T; Xu, Q; Yin, X, 2010) |
| "Asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase (eNOS), is considered to be a risk factor for atherosclerosis." | 7.75 | Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. ( Antoniades, C; Antonopoulos, A; Channon, KM; Cunnington, C; Leeson, P; Pillai, R; Ratnatunga, C; Shirodaria, C; Stefanadis, C; Tousoulis, D; Van-Assche, T; Warrick, N, 2009) |
| "In 289 patients with coronary artery disease we assessed coronary endothelium-dependent and -independent vascular responses to intracoronary infusion of acetylcholine, adenosine, and nitroglycerin, respectively, and determined plasma ADMA and l-arginine concentrations by HPLC." | 7.74 | Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. ( Böger, RH; Lüscher, TF; Maas, R; Quitzau, K; Rafflenbeul, W; Schwedhelm, E; Spieker, L; Steenpass, A, 2007) |
| " We investigated whether plasma levels of the NOS inhibitor asymmetric dimethylarginine (ADMA), of symmetric dimethylarginine (SDMA) and of the nitrogen oxide substrate l-arginine can serve as additional staging biomarkers in stable coronary artery disease, non-ST-segment myocardial infarction (NSTEMI) and ST-segment myocardial infarction (STEMI)." | 7.74 | Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization. ( Frøbert, O; Hjortshøj, SP; Ravkilde, J; Simonsen, U, 2008) |
| "Asymmetrical dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase and has been associated with systemic atherosclerosis; however, the role of ADMA in patients with coronary artery disease (CAD) has not been investigated." | 7.72 | Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. ( Charng, MJ; Ding, YA; Lin, SJ; Lu, TM, 2003) |
| "Metformin, the drug of first choice in type 2 diabetes mellitus (T2DM), reduces cardiovascular (CV) morbidity and mortality in part independently of improved glycemic control and changes in traditional risk factors." | 6.80 | Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. ( Chyrchel, B; Golay, A; Kruszelnicka, O; Surdacki, A, 2015) |
| "Severity of coronary atherosclerosis was estimated by number of diseased vessels." | 5.46 | Increased serum concentrations of asymmetric dimethylarginine (ADMA) in patients with early-onset coronary artery disease. ( Guo, FF; He, GW; Liu, ZF; Lun, LM; Wang, Q; Xuan, C; Zhang, X, 2017) |
| "Early carotid atherosclerosis was defined as a mean CIMT > 1." | 5.42 | Osteoprotegerin is Associated With Endothelial Function and Predicts Early Carotid Atherosclerosis in Patients With Coronary Artery Disease. ( Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Morisawa, T; Nakagomi, A; Shimizu, W, 2015) |
| "ED is associated with established coronary atherosclerosis, but its relationship with early coronary atherosclerosis and CED is unknown." | 5.33 | Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. ( Elesber, AA; Lennon, RJ; Lerman, A; Lerman, LO; Mathew, V; McConnell, JP; Nelson, RE; Prasad, A; Pumper, G; Solomon, H, 2006) |
| " The reduced bioavailability of endothelium-derived nitric oxide (NO) may play a role in endothelial vasodilator dysfunction and the structural changes that are characteristic of GCAD." | 5.33 | Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. ( Cooke, JP; Gunawan, F; Jacobi, J; Robbins, RC; Sydow, K; Tanaka, M; Tsao, PS, 2005) |
| "We previously showed that treatment with folic acid (FA)/B12 was associated with more rapid progression of coronary artery disease (CAD)." | 5.17 | The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine. ( Bleie, O; Borgeraas, H; Løland, KH; Nordrehaug, JE; Nygård, O; Strand, E; Svardal, A; Ueland, PM, 2013) |
| " We sought to investigate whether ranolazine, a novel antianginal medication with no effect on heart rate or blood pressure, improves endothelial function in patients with stable coronary artery disease (CAD)." | 5.14 | Ranolazine improves endothelial function in patients with stable coronary artery disease. ( Coppola, JT; Deshmukh, SH; Hermance, EV; Infantino, MN; Mindrescu, C; Patel, SR; Pinassi, E; Staniloae, CS, 2009) |
| "Studies regarding the predictive utility of the blood level of asymmetric dimethylarginine (ADMA) in patients with coronary artery disease (CAD) have yielded the conflicting findings." | 5.12 | Prognostic value of asymmetric dimethylarginine in patients with coronary artery disease: A meta-analysis. ( Dai, Y; Mao, H; Ye, J; Zhang, J; Zheng, W, 2021) |
| "Pioglitazone rapidly improves endothelial function in non-diabetic patients with coronary artery disease." | 5.12 | Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. ( Ambrose, J; Bernaski, E; Coppola, J; El-Khally, Z; Kurian, D; Mandadi, V; Morlote, M; Pinassi, E; Staniloae, C, 2007) |
| "Nutritional factors such as magnesium, folic acid, vitamins B12 and B6, L-arginine, and polyunsaturated fatty acids (PUFAs) appear to be significantly beneficial for patients with coronary artery disease (CAD), and in the prevention and arresting the progression of HF and cardiac arrhythmias." | 4.91 | Nutritional factors in the prevention and management of coronary artery disease and heart failure. ( Das, UN, 2015) |
| " Thus, together with classic risk factors such as hypertension, dyslipidemia and diabetes, other situations such as microinflammation, increased concentration of asymmetrical dimethyl-L-arginine, disturbed phosphate metabolism and anemia may represent important risk factors for accelerated atherosclerosis in dialyzed patients." | 4.82 | Atherosclerosis in dialyzed patients. ( Ritz, E, 2004) |
| "Previous studies have shown that Asymmetric Dimethyl Arginine (ADMA) is increased significantly during coronary artery diseases (CAD)." | 3.88 | Evaluation of serum Asymmetric Dimethyl Arginine concentrations in coronary artery disease patients without traditional cardiovascular risk factors. ( Ayati, N; Elyasi, S; Ghayour-Mobarhan, M; Mohammadpour, AH; Moohebati, M; Sahebkar, A, 2018) |
| " The aim of our study was to determine the predictive value of plasma asymmetric dimethylarginine (ADMA), homocysteine, and high-sensitivity C-reactive protein (hsCRP) levels for occult coronary artery disease (CAD)." | 3.81 | Predictive value of plasma asymmetric dimethylarginine, homocysteine, and high-sensitive CRP levels in occult coronary artery disease: A multidetector-row computed tomography study. ( Başaran, Y; Geçmen, Ç; Gürel, E; Karaahmet, T; Mutlu, B; Tigen, K, 2015) |
| "Asymmetric dimethylarginine (ADMA) plays role in the pathogenesis of coronary artery disease and related mortality and morbidity through a number of mechanisms." | 3.81 | Asymmetric dimethylarginine is not a good predictor of ischemia using myocardial perfusion scintigraphy. ( Aşik, M; Aslantaş, Y; Bulur, S; Doğan, AS; Erkan, ME; Ilçe, HT; Memişoğullari, R; Uçgun, T; Yildirim, M; Yildiz, N; Yilmaz, A, 2015) |
| "To determine whether 3 biomarkers, L-arginine, asymmetric dimethylarginine (ADMA), and symmetric dimethylarginine (SDMA), can predict outcomes in patients with Kawasaki disease (KD)." | 3.80 | Asymmetric and symmetric dimethylarginine are associated with coronary artery lesions in Kawasaki disease. ( Huang, YH; Kuo, HC; Lee, CP; Tain, YL, 2014) |
| "Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthesis inhibitor, and insulin resistance (IR) have been implicated in atherogenesis." | 3.79 | Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: a cross-sectional study. ( Golay, A; Kruszelnicka, O; Surdacki, A, 2013) |
| "Plasma levels of ADMA, SDMA, L-arginine, and L-arginine/ADMA ratio are reliable and feasible markers of an early ischemia-reperfusion injury." | 3.77 | Effects of coronary revascularization with or without cardiopulmonary bypass on plasma levels of asymmetric dimethylarginine. ( Ajtay, Z; Alotti, N; Bode-Böger, SM; Cziráki, A; Lenkey, Z; Martens-Lobenhoffer, J; Németh, Á; Sulyok, E; Szabados, S; Szabó, C, 2011) |
| "In the present study, we tested whether a novel genetic variant in dimethylarginine dimethylaminohydrolase 1 (DDAH1), an important ADMA hydrolyzing gene, was associated with stroke and coronary heart disease (CHD) susceptibility in the Chinese Han population." | 3.76 | A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease. ( Ding, H; Hui, R; Lu, Z; Shaffer, JR; Wang, DW; Wang, H; Wang, X; Wu, B; Yan, J, 2010) |
| "The endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine (ADMA) is increased in patients with coronary artery disease and may regulate function of circulating angiogenic progenitor cells (APCs) by small regulatory RNAs." | 3.76 | Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. ( Bauersachs, J; Ertl, G; Fiedler, J; Fleissner, F; Galuppo, P; Gupta, SK; Jazbutyte, V; Kneitz, S; Mayr, M; Thum, T; Xu, Q; Yin, X, 2010) |
| "Asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase (eNOS), is considered to be a risk factor for atherosclerosis." | 3.75 | Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. ( Antoniades, C; Antonopoulos, A; Channon, KM; Cunnington, C; Leeson, P; Pillai, R; Ratnatunga, C; Shirodaria, C; Stefanadis, C; Tousoulis, D; Van-Assche, T; Warrick, N, 2009) |
| "We examine the relationship of related posttranslational modification products of arginine methylation and coronary artery disease (CAD) phenotypes." | 3.75 | Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. ( Brennan, DM; Cho, L; Hazen, SL; Tang, WH; Wang, Z, 2009) |
| " However, little information is available about any association between plasma levels of asymmetric dimethylarginine (ADMA), insulin resistance, and CAC." | 3.74 | Coronary artery calcification, ADMA, and insulin resistance in CKD patients. ( Hidekazu, M; Ikee, R; Kobayashi, S; Maesato, K; Mano, T; Ohtake, T; Oka, M, 2008) |
| "In 289 patients with coronary artery disease we assessed coronary endothelium-dependent and -independent vascular responses to intracoronary infusion of acetylcholine, adenosine, and nitroglycerin, respectively, and determined plasma ADMA and l-arginine concentrations by HPLC." | 3.74 | Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia. ( Böger, RH; Lüscher, TF; Maas, R; Quitzau, K; Rafflenbeul, W; Schwedhelm, E; Spieker, L; Steenpass, A, 2007) |
| " We investigated whether plasma levels of the NOS inhibitor asymmetric dimethylarginine (ADMA), of symmetric dimethylarginine (SDMA) and of the nitrogen oxide substrate l-arginine can serve as additional staging biomarkers in stable coronary artery disease, non-ST-segment myocardial infarction (NSTEMI) and ST-segment myocardial infarction (STEMI)." | 3.74 | Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization. ( Frøbert, O; Hjortshøj, SP; Ravkilde, J; Simonsen, U, 2008) |
| "Given that the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, can decrease nitric oxide bioavailability and lead to atherosclerosis, its concentration can be a good predictor for coronary artery disease." | 3.73 | Plasma asymmetric dimethylarginine level and extent of lesion at coronary angiography. ( Biberoglu, G; Cengel, A; Hasanoglu, A; Sahinarslan, A; Timurkaynak, T; Turkoglu, S, 2006) |
| "Asymmetrical dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase and has been associated with systemic atherosclerosis; however, the role of ADMA in patients with coronary artery disease (CAD) has not been investigated." | 3.72 | Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. ( Charng, MJ; Ding, YA; Lin, SJ; Lu, TM, 2003) |
| "Metformin, the drug of first choice in type 2 diabetes mellitus (T2DM), reduces cardiovascular (CV) morbidity and mortality in part independently of improved glycemic control and changes in traditional risk factors." | 2.80 | Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease. ( Chyrchel, B; Golay, A; Kruszelnicka, O; Surdacki, A, 2015) |
| "Thus, subjects with chronic renal failure are exposed to increased morbidity and mortality from cardiovascular events." | 2.44 | Cardiac biomarkers and chronic renal diseases. ( Kristofova, B; Valocik, G; Valocikova, I, 2008) |
| " Hence they affect production and bioavailability of eNOS-derived nitric oxide (NO) and consequently healthy blood vessels." | 1.48 | AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians. ( Abdel Rahman, MF; Amir, M; Gad, MZ; Hassanein, SI, 2018) |
| "Severity of coronary atherosclerosis was estimated by number of diseased vessels." | 1.46 | Increased serum concentrations of asymmetric dimethylarginine (ADMA) in patients with early-onset coronary artery disease. ( Guo, FF; He, GW; Liu, ZF; Lun, LM; Wang, Q; Xuan, C; Zhang, X, 2017) |
| "Early carotid atherosclerosis was defined as a mean CIMT > 1." | 1.42 | Osteoprotegerin is Associated With Endothelial Function and Predicts Early Carotid Atherosclerosis in Patients With Coronary Artery Disease. ( Atarashi, H; Kohashi, K; Kosugi, M; Kusama, Y; Morisawa, T; Nakagomi, A; Shimizu, W, 2015) |
| "53 patients with chronic renal failure receiving hemodialysis treatment and 34 healthy persons were participated to the study." | 1.40 | Levels of arginine and its products in dialysis patients. ( Akyurek, F; Erdem, SS; Kiyici, A; Ozturk, B; Sivrikaya, A; Ugurcu, V; Unlu, A; Vatansev, H, 2014) |
| "Coronary artery ectasia (CAE) is characterized by an abnormal dilatation of the coronary arteries." | 1.36 | Relationship between L-arginine/asymmetric dimethylarginine, homocysteine, folic acid, vitamin B levels, and coronary artery ectasia. ( Ardic, I; Celik, A; Ceyhan, K; Erdem, S; Kadi, H; Kalay, N; Kaya, MG; Koc, F; Onalan, O; Ozbek, K; Sahin, S; Taner, A; Yarlioglues, M, 2010) |
| "While renal failure greatly increases coronary risk, mild renal impairment is not usually considered a major risk factor." | 1.35 | Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. ( Moriatis, M; Naidoo, D; Salonikas, C; Sim, AS; Wang, J; Wang, XL; Wilcken, DE, 2008) |
| "Insulin sensitivity was quantified by a hyperinsulinemic euglycemic clamp technique and expressed as M." | 1.34 | Nontraditional atherosclerotic risk factors and extent of coronary atherosclerosis in patients with combined impaired fasting glucose and impaired glucose tolerance. ( Bode-Böger, SM; Dubiel, JS; Huszno, B; Kawecka-Jaszcz, K; Klecha, A; Martens-Lobenhoffer, J; Stochmal, A; Stochmal, E; Surdacki, A; Szurkowska, M; Szybiński, Z, 2007) |
| "ED is associated with established coronary atherosclerosis, but its relationship with early coronary atherosclerosis and CED is unknown." | 1.33 | Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. ( Elesber, AA; Lennon, RJ; Lerman, A; Lerman, LO; Mathew, V; McConnell, JP; Nelson, RE; Prasad, A; Pumper, G; Solomon, H, 2006) |
| " The reduced bioavailability of endothelium-derived nitric oxide (NO) may play a role in endothelial vasodilator dysfunction and the structural changes that are characteristic of GCAD." | 1.33 | Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. ( Cooke, JP; Gunawan, F; Jacobi, J; Robbins, RC; Sydow, K; Tanaka, M; Tsao, PS, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.32) | 18.2507 |
| 2000's | 26 (34.21) | 29.6817 |
| 2010's | 43 (56.58) | 24.3611 |
| 2020's | 6 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Papageorgiou, N | 2 |
| Theofilis, P | 2 |
| Oikonomou, E | 2 |
| Lazaros, G | 2 |
| Sagris, M | 2 |
| Tousoulis, D | 3 |
| Huang, SS | 1 |
| Huang, WC | 1 |
| Tsai, CT | 1 |
| Chen, YY | 1 |
| Lee, SH | 2 |
| Lu, TM | 2 |
| Parikh, RV | 2 |
| Pargaonkar, V | 1 |
| Ball, RL | 1 |
| Kobayashi, Y | 2 |
| Kimura, T | 1 |
| Yeung, AC | 2 |
| Cooke, JP | 7 |
| Tremmel, JA | 1 |
| Szabo, Z | 1 |
| Bartha, E | 1 |
| Nagy, L | 1 |
| Molnar, T | 1 |
| Bening, C | 1 |
| Sales, VL | 1 |
| Alhussini, K | 1 |
| Radakovic, D | 1 |
| Benitez, RC | 1 |
| Madrahimov, N | 1 |
| Keller, D | 1 |
| Leyh, R | 1 |
| Ye, J | 1 |
| Dai, Y | 1 |
| Mao, H | 1 |
| Zheng, W | 1 |
| Zhang, J | 1 |
| Khush, KK | 1 |
| Luikart, H | 1 |
| Pargaonkar, VS | 1 |
| Lee, JH | 1 |
| Sinha, S | 1 |
| Cohen, G | 1 |
| Valantine, HA | 2 |
| Fearon, WF | 1 |
| Paapstel, K | 1 |
| Kals, J | 1 |
| Eha, J | 1 |
| Tootsi, K | 1 |
| Ottas, A | 1 |
| Piir, A | 1 |
| Jakobson, M | 1 |
| Lieberg, J | 1 |
| Zilmer, M | 1 |
| Rzepecka-Stojko, A | 1 |
| Stojko, J | 1 |
| Jasik, K | 1 |
| Buszman, E | 1 |
| Ghayour-Mobarhan, M | 1 |
| Ayati, N | 2 |
| Sahebkar, A | 1 |
| Moohebati, M | 1 |
| Elyasi, S | 1 |
| Mohammadpour, AH | 1 |
| Amir, M | 1 |
| Hassanein, SI | 1 |
| Abdel Rahman, MF | 1 |
| Gad, MZ | 1 |
| Wieczorek-Surdacka, E | 1 |
| Hanff, E | 1 |
| Chyrchel, B | 3 |
| Kuźniewski, M | 1 |
| Surdacki, A | 5 |
| Tsikas, D | 6 |
| Løland, KH | 1 |
| Bleie, O | 1 |
| Borgeraas, H | 2 |
| Strand, E | 1 |
| Ueland, PM | 2 |
| Svardal, A | 1 |
| Nordrehaug, JE | 1 |
| Nygård, O | 2 |
| Gopu, CL | 1 |
| Hari, PR | 1 |
| George, R | 1 |
| Harikrishnan, S | 1 |
| Sreenivasan, K | 1 |
| Kruszelnicka, O | 3 |
| Golay, A | 2 |
| Gürel, E | 1 |
| Tigen, K | 1 |
| Karaahmet, T | 1 |
| Geçmen, Ç | 1 |
| Mutlu, B | 1 |
| Başaran, Y | 1 |
| Deftereos, S | 1 |
| Bouras, G | 1 |
| Tsounis, D | 1 |
| Papadimitriou, C | 1 |
| Hatzis, G | 1 |
| Raisakis, K | 1 |
| Panagopoulou, V | 1 |
| Kaoukis, A | 1 |
| Ioannidis, A | 1 |
| Deftereos, G | 1 |
| Kossyvakis, C | 1 |
| Manolis, AS | 1 |
| Alexopoulos, D | 1 |
| Stefanadis, C | 2 |
| Cleman, MW | 1 |
| Giannopoulos, G | 1 |
| Yousefi, B | 1 |
| Faghfoori, Z | 1 |
| Samadi, N | 1 |
| Karami, H | 1 |
| Ahmadi, Y | 1 |
| Badalzadeh, R | 1 |
| Shafiei-Irannejad, V | 1 |
| Majidinia, M | 1 |
| Ghavimi, H | 1 |
| Jabbarpour, M | 1 |
| Huang, YH | 1 |
| Tain, YL | 1 |
| Lee, CP | 1 |
| Kuo, HC | 1 |
| Masaki, N | 1 |
| Hakuno, D | 1 |
| Toya, T | 1 |
| Shiraishi, Y | 1 |
| Kujiraoka, T | 1 |
| Namba, T | 1 |
| Yada, H | 1 |
| Kimura, K | 1 |
| Miyazaki, K | 1 |
| Adachi, T | 1 |
| Ugurcu, V | 1 |
| Vatansev, H | 1 |
| Unlu, A | 1 |
| Sivrikaya, A | 1 |
| Akyurek, F | 1 |
| Ozturk, B | 1 |
| Kiyici, A | 1 |
| Erdem, SS | 1 |
| Das, UN | 1 |
| Kayacelebi, AA | 2 |
| Willers, J | 1 |
| Pham, VV | 2 |
| Hahn, A | 1 |
| Schneider, JY | 2 |
| Rothmann, S | 2 |
| Frölich, JC | 2 |
| Can, F | 1 |
| Ziyrek, M | 1 |
| Erdem, Ş | 2 |
| Civan, M | 1 |
| Görmüş, U | 1 |
| Şahin, S | 2 |
| Acar, Z | 1 |
| Çiftçi, Ç | 1 |
| Xuan, C | 2 |
| Tian, QW | 1 |
| Li, H | 1 |
| Zhang, BB | 1 |
| He, GW | 2 |
| Lun, LM | 2 |
| Riccioni, G | 1 |
| Scotti, L | 1 |
| Guagnano, MT | 1 |
| Bosco, G | 1 |
| Bucciarelli, V | 1 |
| Di Ilio, E | 1 |
| Speranza, L | 1 |
| Martini, F | 1 |
| Bucciarelli, T | 1 |
| Yamazaki, H | 1 |
| Yamaguchi, K | 1 |
| Soeki, T | 1 |
| Wakatsuki, T | 1 |
| Niki, T | 1 |
| Taketani, Y | 1 |
| Kitaoka, A | 1 |
| Kusunose, K | 1 |
| Ise, T | 1 |
| Tobiume, T | 1 |
| Yagi, S | 1 |
| Iwase, T | 1 |
| Yamada, H | 1 |
| Sata, M | 1 |
| Langen, J | 1 |
| Weigt-Usinger, K | 1 |
| Chobanyan-Jürgens, K | 1 |
| Mariotti, F | 1 |
| Atzler, D | 1 |
| Choe, CU | 1 |
| Schwedhelm, E | 2 |
| Huneau, JF | 1 |
| Lücke, T | 1 |
| Erkan, ME | 1 |
| Aşik, M | 1 |
| Uçgun, T | 1 |
| Yildiz, N | 1 |
| Yilmaz, A | 1 |
| Aslantaş, Y | 1 |
| Bulur, S | 1 |
| Ilçe, HT | 1 |
| Yildirim, M | 1 |
| Memişoğullari, R | 1 |
| Doğan, AS | 1 |
| Morisawa, T | 1 |
| Nakagomi, A | 1 |
| Kohashi, K | 1 |
| Kosugi, M | 1 |
| Kusama, Y | 1 |
| Atarashi, H | 1 |
| Shimizu, W | 1 |
| Hertel, JK | 1 |
| Seifert, R | 1 |
| Berge, RK | 1 |
| Bohov, P | 1 |
| Hjelmesæth, J | 1 |
| Świerszcz, J | 1 |
| Bednarek, J | 1 |
| Nessler, J | 1 |
| Ilic, MD | 1 |
| Pavlovic, R | 1 |
| Lazarevic, G | 1 |
| Zivanovic, S | 1 |
| Cvetkovic, T | 1 |
| Kocic, G | 1 |
| Ilic, S | 1 |
| Ambrosio, G | 1 |
| Sun, L | 1 |
| Bai, Y | 1 |
| Zhao, R | 1 |
| Sun, T | 2 |
| Cao, R | 1 |
| Wang, F | 1 |
| He, G | 1 |
| Zhang, W | 1 |
| Chen, Y | 1 |
| Ye, P | 1 |
| Du, G | 1 |
| Mangiacapra, F | 1 |
| Conte, M | 1 |
| Demartini, C | 1 |
| Muller, O | 1 |
| Delrue, L | 1 |
| Dierickx, K | 1 |
| Di Sciascio, G | 1 |
| Trimarco, B | 1 |
| De Bruyne, B | 1 |
| Wijns, W | 1 |
| Bartunek, J | 1 |
| Barbato, E | 1 |
| Tariq, K | 1 |
| Khan, MA | 1 |
| Liu, ZF | 1 |
| Wang, Q | 1 |
| Guo, FF | 1 |
| Zhang, X | 1 |
| Kobayashi, S | 1 |
| Oka, M | 1 |
| Maesato, K | 1 |
| Ikee, R | 1 |
| Mano, T | 1 |
| Hidekazu, M | 1 |
| Ohtake, T | 1 |
| Valocikova, I | 1 |
| Kristofova, B | 1 |
| Valocik, G | 1 |
| Antoniades, C | 1 |
| Shirodaria, C | 1 |
| Leeson, P | 1 |
| Antonopoulos, A | 1 |
| Warrick, N | 1 |
| Van-Assche, T | 1 |
| Cunnington, C | 1 |
| Pillai, R | 1 |
| Ratnatunga, C | 1 |
| Channon, KM | 1 |
| Deshmukh, SH | 1 |
| Patel, SR | 1 |
| Pinassi, E | 2 |
| Mindrescu, C | 1 |
| Hermance, EV | 1 |
| Infantino, MN | 1 |
| Coppola, JT | 1 |
| Staniloae, CS | 1 |
| Wang, Z | 1 |
| Tang, WH | 1 |
| Cho, L | 1 |
| Brennan, DM | 1 |
| Hazen, SL | 1 |
| Huang, Y | 1 |
| Phillips, MI | 1 |
| Luo, X | 1 |
| Zhu, J | 1 |
| Shi, H | 1 |
| Li, J | 1 |
| Aktoz, T | 1 |
| Aktoz, M | 1 |
| Tatlı, E | 1 |
| Kaplan, M | 1 |
| Turan, FN | 1 |
| Barutcu, A | 1 |
| Atakan, IH | 1 |
| Demir, M | 1 |
| Altun, A | 1 |
| Ding, H | 1 |
| Wu, B | 1 |
| Wang, H | 1 |
| Lu, Z | 1 |
| Yan, J | 1 |
| Wang, X | 1 |
| Shaffer, JR | 1 |
| Hui, R | 1 |
| Wang, DW | 1 |
| Sharma, P | 1 |
| Bentley, P | 1 |
| Guo, YJ | 1 |
| Chen, L | 1 |
| Bai, YP | 1 |
| Li, L | 1 |
| Sun, J | 1 |
| Zhang, GG | 1 |
| Yang, TL | 1 |
| Xia, J | 1 |
| Li, YJ | 1 |
| Chen, XP | 1 |
| Fleissner, F | 1 |
| Jazbutyte, V | 1 |
| Fiedler, J | 1 |
| Gupta, SK | 1 |
| Yin, X | 1 |
| Xu, Q | 1 |
| Galuppo, P | 1 |
| Kneitz, S | 1 |
| Mayr, M | 1 |
| Ertl, G | 3 |
| Bauersachs, J | 4 |
| Thum, T | 4 |
| Koc, F | 1 |
| Ardic, I | 1 |
| Kalay, N | 1 |
| Ozbek, K | 1 |
| Yarlioglues, M | 1 |
| Ceyhan, K | 1 |
| Celik, A | 1 |
| Kadi, H | 1 |
| Taner, A | 1 |
| Onalan, O | 1 |
| Kaya, MG | 1 |
| Wolf, C | 1 |
| Lorenzen, JM | 1 |
| Stein, S | 2 |
| Störk, S | 1 |
| Weidemann, F | 1 |
| Anker, SD | 2 |
| Cziráki, A | 1 |
| Ajtay, Z | 1 |
| Németh, Á | 1 |
| Lenkey, Z | 1 |
| Sulyok, E | 1 |
| Szabados, S | 1 |
| Alotti, N | 1 |
| Martens-Lobenhoffer, J | 2 |
| Szabó, C | 1 |
| Bode-Böger, SM | 2 |
| Jang, JJ | 1 |
| Berkheimer, SB | 1 |
| Merchant, M | 1 |
| Krishnaswami, A | 1 |
| Işıklar, OO | 1 |
| Barutcuoğlu, B | 1 |
| Kabaroğlu, C | 1 |
| Mutaf, I | 1 |
| Özmen, D | 1 |
| Bayındır, O | 1 |
| Zoghi, M | 1 |
| Uluer, H | 1 |
| Weis, M | 2 |
| Ding, YA | 1 |
| Charng, MJ | 1 |
| Lin, SJ | 1 |
| Kledal, TN | 1 |
| Lin, KY | 1 |
| Panchal, SN | 1 |
| Gao, SZ | 1 |
| Mocarski, ES | 1 |
| Ritz, E | 1 |
| Tsuda, K | 1 |
| Nishio, I | 1 |
| Bae, SW | 1 |
| Stühlinger, MC | 1 |
| Yoo, HS | 1 |
| Yu, KH | 1 |
| Park, HK | 1 |
| Choi, BY | 1 |
| Lee, YS | 1 |
| Pachinger, O | 1 |
| Choi, YH | 1 |
| Park, JE | 1 |
| Tanaka, M | 1 |
| Sydow, K | 2 |
| Gunawan, F | 1 |
| Jacobi, J | 1 |
| Tsao, PS | 1 |
| Robbins, RC | 1 |
| Schultheiss, M | 1 |
| Eigenthaler, M | 1 |
| Poole-Wilson, PA | 1 |
| Kawata, T | 1 |
| Daimon, M | 1 |
| Hasegawa, R | 1 |
| Teramoto, K | 1 |
| Toyoda, T | 1 |
| Sekine, T | 1 |
| Yamamoto, K | 1 |
| Uchida, D | 1 |
| Himi, T | 1 |
| Yoshida, K | 1 |
| Komuro, I | 1 |
| Elesber, AA | 1 |
| Solomon, H | 1 |
| Lennon, RJ | 1 |
| Mathew, V | 1 |
| Prasad, A | 1 |
| Pumper, G | 1 |
| Nelson, RE | 1 |
| McConnell, JP | 1 |
| Lerman, LO | 1 |
| Lerman, A | 1 |
| Maas, R | 2 |
| Quitzau, K | 1 |
| Spieker, L | 1 |
| Rafflenbeul, W | 1 |
| Steenpass, A | 1 |
| Lüscher, TF | 1 |
| Böger, RH | 2 |
| Becker, T | 1 |
| Chobanyan, K | 1 |
| Mitschke, A | 1 |
| Beckmann, B | 1 |
| Gutzki, FM | 1 |
| Stichtenoth, DO | 1 |
| Sahinarslan, A | 1 |
| Cengel, A | 1 |
| Biberoglu, G | 1 |
| Hasanoglu, A | 1 |
| Turkoglu, S | 1 |
| Timurkaynak, T | 1 |
| Staniloae, C | 1 |
| Mandadi, V | 1 |
| Kurian, D | 1 |
| Coppola, J | 1 |
| Bernaski, E | 1 |
| El-Khally, Z | 1 |
| Morlote, M | 1 |
| Ambrose, J | 1 |
| Stochmal, E | 1 |
| Szurkowska, M | 1 |
| Stochmal, A | 1 |
| Klecha, A | 1 |
| Kawecka-Jaszcz, K | 1 |
| Dubiel, JS | 1 |
| Huszno, B | 1 |
| Szybiński, Z | 1 |
| Kielstein, JT | 1 |
| Weber, T | 1 |
| Auer, J | 1 |
| Lamm, G | 1 |
| Lassnig, E | 1 |
| Rammer, M | 1 |
| O'Rourke, MF | 1 |
| Eber, B | 1 |
| Iribarren, C | 1 |
| Husson, G | 1 |
| Wang, BY | 1 |
| Sidney, S | 1 |
| Frøbert, O | 1 |
| Hjortshøj, SP | 1 |
| Simonsen, U | 1 |
| Ravkilde, J | 1 |
| Joyal, D | 1 |
| Leya, F | 1 |
| Obada Al-Chekakie, M | 1 |
| Arab, D | 1 |
| Dieter, RS | 1 |
| Morshedi-Meibodi, A | 1 |
| Lewis, B | 1 |
| Steen, L | 1 |
| Fareed, J | 1 |
| Hoppenstead, D | 1 |
| Akar, JG | 1 |
| Wang, J | 1 |
| Sim, AS | 1 |
| Wang, XL | 1 |
| Salonikas, C | 1 |
| Moriatis, M | 1 |
| Naidoo, D | 1 |
| Wilcken, DE | 1 |
| Miyazaki, H | 1 |
| Matsuoka, H | 1 |
| Usui, M | 1 |
| Ueda, S | 1 |
| Okuda, S | 1 |
| Imaizumi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sex Differences in Symptomatic Non-Obstructive Coronary Disease: Do Women Have a Unique Coronary Pathophysiology?[NCT00823563] | 126 participants (Anticipated) | Observational | 2007-06-30 | Recruiting | |||
| A Randomised Double Blind Study of the Effects of Homocysteine Lowering Therapy on Mortality and Cardiac Events in Patients Undergoing Coronary Angiography[NCT00354081] | Phase 3 | 3,096 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Reduction of Symptomatic Ventricular Premature Beats With Ranolazine[NCT01996618] | Phase 4 | 72 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Does Ranolazine Decrease Biomarkers That Indicate Evidence of Myocardial Damage in Diabetics With Stable Ischemic Heart Disease? A Double-blinded, Randomized, Placebo Controlled Trial[NCT02611596] | 0 participants (Actual) | Interventional | 2016-11-30 | Withdrawn | |||
| Low Fat Vegan Diet or American Heart Association Diet, Impact on Biomarkers of Inflammation, Oxidative Stress and Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol: A Four Week Randomized Trial[NCT01817491] | 60 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| Adiposity and Airway Inflammation in HIV-Associated Airway Disease[NCT02975258] | 102 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
PAQ self reported questions based on activity level from 1 (low activity) to 5 (high activity), overall PAQ score is a mean of the questions. (NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Reduced Fat Vegan Diet | 0.22 |
| American Heart Association Diet | -0.16 |
Body mass index z-scores, also called BMI standard deviation (s.d.) scores, are measures of relative weight adjusted for child age and sex. Given a child's age, sex, BMI, and an appropriate reference standard, a BMI z-score (or its equivalent BMI-for-age percentile) can be determined. Negative BMI z-scores indicate a BMI that is lower than the population mean, while positive BMI scores indicate a value that is higher than the population mean. A decrease in the BMI z-score over time indicate a lowering of the BMI. Z-scores of 1.03 and 1.64 correspond to the 85th and 95th percentiles of BMI-for-age, which are the definitions of overweight and obesity in children. (NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | Z Score (Mean) |
|---|---|
| Reduced Fat Vegan Diet | -0.14 |
| American Heart Association Diet | -0.03 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | Z score (Mean) |
|---|---|
| PB/AHA | -0.13 |
PAQ self reported questions based on activity level from 1 (low activity) to 5 (high activity), overall PAQ score is a mean of the questions. (NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| PB/AHA | 0.39 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mm Hg (Mean) | |||
|---|---|---|---|---|
| Children Systolic BP | Parents Systolic BP | Children Diastolic BP | Parent Diastolic BP | |
| American Heart Association Diet | -5.14 | -3.14 | -4.36 | -6.64 |
| Reduced Fat Vegan Diet | -6.43 | -7.96 | -2.61 | -3.46 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | -0.08 | -0.73 |
| Reduced Fat Vegan Diet | -1.12 | -1.29 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | cm (Mean) | |||
|---|---|---|---|---|
| Children Waist Circumference | Parents Waist Circumference | Children Midarm Circumference | Parents Midarm Circumference | |
| American Heart Association Diet | -2.96 | -0.49 | -1.14 | 0.35 |
| Reduced Fat Vegan Diet | -1.53 | -1.94 | -2.02 | -1.32 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -.64 | -5.43 |
| Reduced Fat Vegan Diet | 0.93 | 4.93 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | 0.21 | 0.14 |
| Reduced Fat Vegan Diet | 0.17 | -0.16 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/L (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | 2.78 | 0.21 |
| Reduced Fat Vegan Diet | -2.09 | -0.24 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -0.19 | -0.19 |
| Reduced Fat Vegan Diet | -0.17 | 0.16 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | uU/ml (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | 3.16 | -3.15 |
| Reduced Fat Vegan Diet | -5.42 | -3.11 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | mg/dL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| total cholesterol children | triglycerides children | high-density lipoprotein cholesterol children | low-density lipoprotein cholesterol children | total cholesterol parents | triglycerides parents | high-density lipoprotein cholesterol parents | low-density lipoprotein cholesterol parents | |
| American Heart Association Diet | -16.50 | -13.14 | -2.93 | -11.00 | -7.14 | 16.86 | 16.86 | -5.50 |
| Reduced Fat Vegan Diet | -22.50 | -25.50 | -5.93 | -13.14 | -33.79 | 6.21 | -8.14 | -27.00 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | U/L (Mean) | |||
|---|---|---|---|---|
| alanine aminotransferase (ALT) children | aspartate aminotransferase (AST) children | alanine aminotransferase (ALT) parents | aspartate aminotransferase (AST) parents | |
| American Heart Association Diet | -1.14 | 0.00 | 4.57 | 4.43 |
| Reduced Fat Vegan Diet | 0.79 | 2.79 | 0.86 | 0.14 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | pmol/L (Mean) | |
|---|---|---|
| Children | Parent | |
| American Heart Association Diet | -69.23 | 1.78 |
| Reduced Fat Vegan Diet | -75.34 | 16.91 |
(NCT01817491)
Timeframe: baseline, 4 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Children | Parents | |
| American Heart Association Diet | -1.55 | -2.01 |
| Reduced Fat Vegan Diet | -3.05 | -3.64 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| Children adj mean ratio systolic BP | Children adj mean ratio diastolic BP | parents adj mean ratio systolic BP | parents adj mean ratio diastolic BP | |
| PB/AHA | 1.87 | 1.01 | 0.97 | 1.03 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | percentile (Mean) | |
|---|---|---|
| Children Change in BMI | Parents Change in BMI | |
| PB/AHA | -1.17 | -0.69 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | cm (Mean) | |||
|---|---|---|---|---|
| children waist circumference | parents waist circumference | children arm circumference | parents arm circumference | |
| PB/AHA | 1.32 | -1.14 | -1.25 | -1.68 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | kg (Mean) | |
|---|---|---|
| Children Weight | Parents Weight | |
| PB/AHA | -1.71 | -1.95 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | mg/dL (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| CHOL children | TRIG children | HDL children | LDL children | CHOL parents | TRIG parents | HDL parents | LDL parents | |
| PB/AHA | -10.34 | 1.01 | 0.17 | 0.95 | -27.29 | 0.95 | 0.94 | -21.92 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 1.01 | 1.06 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.99 | 0.96 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.46 | 0.68 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.26 | 1.14 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.7 | 0.87 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| ALT children | AST children | ALT parents | AST parents | |
| PB/AHA | 1 | 1.13 | 0.85 | 0.83 |
(NCT01817491)
Timeframe: Baseline, 4 weeks
| Intervention | ratio (Mean) | |
|---|---|---|
| Children | Parents | |
| PB/AHA | 0.95 | 0.93 |
6 reviews available for n(g),n(g')-dimethyl-l-arginine and Coronary Artery Disease
| Article | Year |
|---|---|
Prognostic value of asymmetric dimethylarginine in patients with coronary artery disease: A meta-analysis.
Topics: Arginine; Biomarkers; Coronary Artery Disease; Humans; Prognosis | 2021 |
Nutritional factors in the prevention and management of coronary artery disease and heart failure.
Topics: Alprostadil; Anti-Inflammatory Agents; Arginine; CD59 Antigens; Coronary Artery Disease; Diabetes Me | 2015 |
Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: A meta-analysis based on 4713 participants.
Topics: Adult; Aged; Arginine; Biomarkers; Case-Control Studies; Coronary Artery Disease; Female; Humans; Ma | 2016 |
Cardiac biomarkers and chronic renal diseases.
Topics: Animals; Arginine; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Disease Progression; Hom | 2008 |
Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway.
Topics: Animals; Arginine; Cardiovascular Agents; Coronary Artery Disease; Endothelium, Vascular; Graft Reje | 2003 |
Atherosclerosis in dialyzed patients.
Topics: Anemia; Animals; Arginine; Arteriosclerosis; Biomarkers; Cause of Death; Comorbidity; Coronary Arter | 2004 |
8 trials available for n(g),n(g')-dimethyl-l-arginine and Coronary Artery Disease
| Article | Year |
|---|---|
Impact of Asymmetric Dimethylarginine on Coronary Physiology Early After Heart Transplantation.
Topics: Arginine; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationshi | 2017 |
The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine.
Topics: Adenosine; Aged; Arginine; Coronary Angiography; Coronary Artery Disease; Disease Progression; Ethio | 2013 |
Plasma homoarginine, arginine, asymmetric dimethylarginine and total homocysteine interrelationships in rheumatoid arthritis, coronary artery disease and peripheral artery occlusion disease.
Topics: Aged; Arginine; Arthritis, Rheumatoid; Coronary Artery Disease; Female; Homoarginine; Homocysteine; | 2015 |
Differential associations of circulating asymmetric dimethylarginine and cell adhesion molecules with metformin use in patients with type 2 diabetes mellitus and stable coronary artery disease.
Topics: Aged; Aged, 80 and over; Arginine; Cell Adhesion Molecules; Coronary Artery Disease; Diabetes Mellit | 2015 |
Impact of Indoxyl Sulfate, a Uremic Toxin, on Non-Culprit Coronary Plaque Composition Assessed on Integrated Backscatter Intravascular Ultrasound.
Topics: Aged; Arginine; Biomarkers; Coronary Artery Disease; Female; Humans; Indican; Male; Middle Aged; Pla | 2015 |
Biosynthesis of homoarginine (hArg) and asymmetric dimethylarginine (ADMA) from acutely and chronically administered free L-arginine in humans.
Topics: Adolescent; Adult; Amidinotransferases; Amino Acid Metabolism, Inborn Errors; Animals; Arginine; Chi | 2015 |
Ranolazine improves endothelial function in patients with stable coronary artery disease.
Topics: Acetanilides; Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Agents; Coronary Artery | 2009 |
Ranolazine improves endothelial function in patients with stable coronary artery disease.
Topics: Acetanilides; Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Agents; Coronary Artery | 2009 |
Ranolazine improves endothelial function in patients with stable coronary artery disease.
Topics: Acetanilides; Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Agents; Coronary Artery | 2009 |
Ranolazine improves endothelial function in patients with stable coronary artery disease.
Topics: Acetanilides; Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Agents; Coronary Artery | 2009 |
Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease.
Topics: Adult; Aged; Arginine; Blood Sedimentation; Brachial Artery; C-Reactive Protein; Cardiovascular Agen | 2007 |
62 other studies available for n(g),n(g')-dimethyl-l-arginine and Coronary Artery Disease
| Article | Year |
|---|---|
Asymmetric Dimethylarginine as a Biomarker in Coronary Artery Disease.
Topics: Arginine; Atherosclerosis; Biomarkers; Coronary Artery Disease; Humans; Risk Factors | 2023 |
Asymmetric Dimethylarginine as a Biomarker in Coronary Artery Disease.
Topics: Arginine; Atherosclerosis; Biomarkers; Coronary Artery Disease; Humans; Risk Factors | 2023 |
Asymmetric Dimethylarginine as a Biomarker in Coronary Artery Disease.
Topics: Arginine; Atherosclerosis; Biomarkers; Coronary Artery Disease; Humans; Risk Factors | 2023 |
Asymmetric Dimethylarginine as a Biomarker in Coronary Artery Disease.
Topics: Arginine; Atherosclerosis; Biomarkers; Coronary Artery Disease; Humans; Risk Factors | 2023 |
Plasma asymmetric dimethylarginine is associated with vulnerable plaque and long-term outcomes in stable coronary artery disease.
Topics: Calcium; Calcium, Dietary; Coronary Artery Disease; Humans; Lipids; Percutaneous Coronary Interventi | 2023 |
Asymmetric dimethylarginine predicts impaired epicardial coronary vasomotion in patients with angina in the absence of obstructive coronary artery disease.
Topics: Angina Pectoris; Arginine; Biomarkers; Coronary Angiography; Coronary Artery Disease; Coronary Vesse | 2020 |
Increased symmetric dimethylarginine, but not asymmetric dimethylarginine, concentrations are associated with transient myocardial ischemia and predict outcome.
Topics: Aged; Arginine; Biomarkers; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Dipyrid | 2020 |
Clinically inapparent right heart dysfunction is associated with reduced myofilament force development in coronary artery disease.
Topics: Aged; Arginine; Asymptomatic Diseases; Biomarkers; C-Reactive Protein; Calcium; Coronary Artery Bypa | 2021 |
Inverse relations of serum phosphatidylcholines and lysophosphatidylcholines with vascular damage and heart rate in patients with atherosclerosis.
Topics: Aged; Angiography, Digital Subtraction; Arginine; Biomarkers; Case-Control Studies; Coronary Artery | 2018 |
Anti-Atherogenic Activity of Polyphenol-Rich Extract from Bee Pollen.
Topics: Angiotensin II; Animals; Arginine; Atherosclerosis; Bees; Cholesterol; Coronary Artery Disease; Diet | 2017 |
Evaluation of serum Asymmetric Dimethyl Arginine concentrations in coronary artery disease patients without traditional cardiovascular risk factors.
Topics: Arginine; Biomarkers; Case-Control Studies; Coronary Artery Disease; Coronary Stenosis; Female; Huma | 2018 |
AGXT2 and DDAH-1 genetic variants are highly correlated with serum ADMA and SDMA levels and with incidence of coronary artery disease in Egyptians.
Topics: Adult; Amidohydrolases; Arginine; Case-Control Studies; Coronary Artery Disease; Egypt; Female; Gene | 2018 |
Distinct associations between plasma osteoprotegerin, homoarginine and asymmetric dimethylarginine in chronic kidney disease male patients with coronary artery disease.
Topics: Aged; Arginine; Biomarkers; Coronary Artery Disease; Homoarginine; Humans; Male; Middle Aged; Osteop | 2019 |
Simultaneous determination of homocysteine and asymmetric dimethylarginine in human urine by liquid chromatography-tandem mass spectrometry.
Topics: Arginine; Biomarkers; Chromatography, Liquid; Coronary Artery Disease; Homocysteine; Humans; Limit o | 2013 |
Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: a cross-sectional study.
Topics: Adult; Aged; Angina, Stable; Arginine; Biomarkers; Blood Glucose; Case-Control Studies; Coronary Ang | 2013 |
Predictive value of plasma asymmetric dimethylarginine, homocysteine, and high-sensitive CRP levels in occult coronary artery disease: A multidetector-row computed tomography study.
Topics: Arginine; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Female; Homocysteine; Humans; Mal | 2015 |
Association of asymmetric dimethylarginine levels with treadmill-stress-test-derived prognosticators.
Topics: Aged; Arginine; Biomarkers; Coronary Artery Disease; Exercise Test; Female; Humans; Male; Middle Age | 2014 |
The effects of Ramadan fasting on endothelial function in patients with cardiovascular diseases.
Topics: Adult; Arginine; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Artery Disease; Endoth | 2014 |
Asymmetric and symmetric dimethylarginine are associated with coronary artery lesions in Kawasaki disease.
Topics: Arginine; Biomarkers; Child, Preschool; Coronary Artery Disease; Coronary Vessels; Female; Humans; I | 2014 |
Association between brachial-ankle pulse wave velocity and the ratio of l-arginine to asymmetric dimethylarginine in patients undergoing coronary angiography.
Topics: Aged; Ankle Brachial Index; Arginine; Blood Pressure; Coronary Angiography; Coronary Artery Disease; | 2015 |
Levels of arginine and its products in dialysis patients.
Topics: Adult; Aged; Arginine; Coronary Artery Disease; Female; Humans; Kidney Failure, Chronic; Male; Middl | 2014 |
The association between coronary atherosclerotic burden and asymmetric dimethylarginine, carotis intima media thickness and endothelial function.
Topics: Aged; Arginine; Biomarkers; Brachial Artery; Carotid Intima-Media Thickness; Cholesterol; Cholestero | 2014 |
Physical exercise reduces synthesis of ADMA, SDMA, and L-Arg.
Topics: Arginine; Biomarkers; Coronary Artery Disease; Exercise; Female; Humans; Male; Middle Aged; Nitric O | 2015 |
Asymmetric dimethylarginine is not a good predictor of ischemia using myocardial perfusion scintigraphy.
Topics: Arginine; Coronary Artery Disease; Echocardiography; Female; Humans; Ischemia; Male; Middle Aged; My | 2015 |
Osteoprotegerin is Associated With Endothelial Function and Predicts Early Carotid Atherosclerosis in Patients With Coronary Artery Disease.
Topics: Aged; Arginine; Biomarkers; Carotid Artery Diseases; Carotid Intima-Media Thickness; Coronary Angiog | 2015 |
Serum trans fatty acids, asymmetric dimethylarginine and risk of acute myocardial infarction and mortality in patients with suspected coronary heart disease: a prospective cohort study.
Topics: Aged; Arginine; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; P | 2016 |
Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Arginine; Coronary Artery Disease; Cross-Sectional St | 2016 |
Detrimental effects of a bout of physical exercise on circulating endogenous inhibitors of endothelial function in patients with coronary artery disease.
Topics: Adult; Aged; Arginine; Biomarkers; Case-Control Studies; Coronary Artery Disease; Echocardiography; | 2017 |
Oncological miR-182-3p, a Novel Smooth Muscle Cell Phenotype Modulator, Evidences From Model Rats and Patients.
Topics: Animals; Arginine; Carotid Artery Diseases; Carotid Artery Injuries; Cell Differentiation; Cell Move | 2016 |
Relationship of asymmetric dimethylarginine (ADMA) with extent and functional severity of coronary atherosclerosis.
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Coronary Angiography; Coronary Artery Disease; Female | 2016 |
Asymmetrical dimethyl arginine in type 2 diabetic patients with coronary artery disease.
Topics: Adult; Arginine; Blood Glucose; Case-Control Studies; Coronary Artery Disease; Cross-Sectional Studi | 2016 |
Increased serum concentrations of asymmetric dimethylarginine (ADMA) in patients with early-onset coronary artery disease.
Topics: Age of Onset; Arginine; Coronary Artery Disease; Coronary Vessels; Female; Humans; Male; Middle Aged | 2017 |
Coronary artery calcification, ADMA, and insulin resistance in CKD patients.
Topics: Aged; Arginine; Calcinosis; Case-Control Studies; Chronic Disease; Coronary Angiography; Coronary Ar | 2008 |
Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis.
Topics: Aged; Arginine; Atherosclerosis; Coronary Artery Bypass; Coronary Artery Disease; Endothelium, Vascu | 2009 |
Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition.
Topics: Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Chromatography, High Pressu | 2009 |
Growth differentiation factor 15 and coronary collateral formation.
Topics: Aged; Analysis of Variance; Arginine; Collateral Circulation; Coronary Angiography; Coronary Artery | 2010 |
Assessment of the relationship between asymmetric dimethylarginine and severity of erectile dysfunction and coronary artery disease.
Topics: Arginine; Coronary Artery Disease; Erectile Dysfunction; Humans; Male; Middle Aged; Severity of Illn | 2010 |
A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease.
Topics: Aged; Amidohydrolases; Arginine; Asian People; Binding Sites; Biomarkers; Case-Control Studies; Cell | 2010 |
Down but not out: candidate gene-based studies still have value in a world dominated by whole genome approaches.
Topics: Amidohydrolases; Arginine; Asian People; Biomarkers; China; Coronary Artery Disease; Evidence-Based | 2010 |
The ALDH2 Glu504Lys polymorphism is associated with coronary artery disease in Han Chinese: Relation with endothelial ADMA levels.
Topics: Aged; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Arginine; China; Coronary Arter | 2010 |
Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism.
Topics: Angiogenesis Inhibitors; Arginine; Coronary Artery Disease; Gene Expression Regulation; Humans; Micr | 2010 |
Relationship between L-arginine/asymmetric dimethylarginine, homocysteine, folic acid, vitamin B levels, and coronary artery ectasia.
Topics: Aged; Arginine; Biomarkers; Case-Control Studies; Chromatography, High Pressure Liquid; Coronary Ang | 2010 |
Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Biomarkers; Coronary Artery Disease; Female; Humans; Male; | 2012 |
Effects of coronary revascularization with or without cardiopulmonary bypass on plasma levels of asymmetric dimethylarginine.
Topics: Aged; Arginine; Biomarkers; Cardiopulmonary Bypass; Chromatography, High Pressure Liquid; Coronary A | 2011 |
Asymmetric dimethylarginine and coronary artery calcium scores are increased in patients infected with human immunodeficiency virus.
Topics: Adult; Arginine; Biomarkers; Calcinosis; California; Case-Control Studies; Chi-Square Distribution; | 2011 |
Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in patients with coronary artery diseases?
Topics: Adult; Aged; Arginine; Atherosclerosis; Coronary Artery Disease; Female; Homocysteine; Humans; Male; | 2012 |
Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease.
Topics: Aged; Arginine; Biomarkers; Coronary Angiography; Coronary Artery Disease; Exercise Test; Female; Hu | 2003 |
Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.
Topics: Amidohydrolases; Arginine; Cardiovascular Diseases; Cells, Cultured; Coronary Angiography; Coronary | 2004 |
Sex hormones and asymmetric dimethylarginine in transplant arteriosclerosis.
Topics: Arginine; Coronary Artery Disease; Endothelium, Vascular; Estrogens; Female; Gonadal Steroid Hormone | 2004 |
Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment.
Topics: Adult; Aged; alpha-Tocopherol; Angina, Unstable; Angioplasty, Balloon, Coronary; Arginine; C-Reactiv | 2005 |
Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease.
Topics: Amidohydrolases; Animals; Arginine; Coronary Artery Disease; Cytokines; Enzyme Inhibitors; Female; H | 2005 |
Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine.
Topics: Arginine; Cell Count; Cells, Cultured; Coronary Artery Disease; Endothelium, Vascular; Enzyme Inhibi | 2005 |
Serum asymmetric dimethylarginine as a marker of coronary microcirculation in patients with non-insulin dependent diabetes mellitus: correlation with coronary flow reserve.
Topics: Aged; Arginine; Biomarkers; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Diab | 2005 |
Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis.
Topics: Arginine; C-Reactive Protein; Coronary Artery Disease; Endothelium, Vascular; Erectile Dysfunction; | 2006 |
Asymmetrical dimethylarginine (ADMA) and coronary endothelial function in patients with coronary artery disease and mild hypercholesterolemia.
Topics: Acetylcholine; Adenosine; Aged; Arginine; Coronary Artery Disease; Endothelium, Vascular; Female; Hu | 2007 |
Accurate quantification of dimethylamine (DMA) in human urine by gas chromatography-mass spectrometry as pentafluorobenzamide derivative: evaluation of the relationship between DMA and its precursor asymmetric dimethylarginine (ADMA) in health and disease
Topics: Acetazolamide; Adult; Arginine; Benzamides; Circadian Rhythm; Coronary Artery Disease; Dimethylamine | 2007 |
Plasma asymmetric dimethylarginine level and extent of lesion at coronary angiography.
Topics: Adolescent; Adult; Aged; Angina Pectoris; Arginine; Coronary Angiography; Coronary Artery Disease; F | 2006 |
Nontraditional atherosclerotic risk factors and extent of coronary atherosclerosis in patients with combined impaired fasting glucose and impaired glucose tolerance.
Topics: Adult; Aged; Arginine; Blood Glucose; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Disc | 2007 |
Should we measure asymmetric dimethylarginine in patients with coronary artery disease?
Topics: Arginine; Biomarkers; Cardiovascular Diseases; Coronary Artery Disease; Humans; Mortality; Predictiv | 2007 |
Arterial wave reflections and determinants of endothelial function a hypothesis based on peripheral mode of action.
Topics: Age Factors; Aged; Aorta; Arginine; Blood Flow Velocity; Blood Pressure; Coronary Artery Disease; Cr | 2007 |
Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: the CARDIA Study.
Topics: Adult; Analysis of Variance; Arginine; Biomarkers; Calcinosis; Case-Control Studies; Coronary Artery | 2007 |
Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization.
Topics: Angioplasty, Balloon, Coronary; Arginine; Biomarkers; Chromatography, High Pressure Liquid; Coronary | 2008 |
Presence of asymmetric dimethylarginine gradients across high-grade lesions in patients with coronary artery disease.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Arginine; Atherosclerosis; Biomarkers; Coronary Artery D | 2007 |
Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease.
Topics: Age Factors; Aged; Arginine; Biomarkers; Cohort Studies; Coronary Artery Disease; Cystatin C; Cystat | 2008 |
[Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis].
Topics: Arginine; Biomarkers; Coronary Artery Disease; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; | 1999 |